MARKET INSIGHT: Insulin delivery techs and the role of long-term cost structures
This article was originally published in Clinica
Executive Summary
Uptake of insulin pump therapy varies sharply from market to market. In the US, over a third of Type I diabetics use a pump, but in Europe this can be as low as the mid-single digits. The speed of new technology roll-outs can be affected by the previous therapy policy of any particular country, but are stakeholders doing enough to ensure that more eligible individuals can access this proven delivery means? IBI principal analyst Ashley Yeo investigates
You may also be interested in...
DTx And Drug Deal Sees Closed Loop Medicine And Teva Team Up On Precision Care
Medicines are still typically prescribed based on average effects in a population and rarely dose-optimized for the individual, says Closed Loop Medicine. The company sees a new strategic partnership with Teva UK as another step in advancing personalized medicine.
Swiss-EU Standoff Set To End? Medtechs Eye MRA Action
Negotiations aimed at renewing the close trading relationship and barrier-free mutual market access between Switzerland and the EU got underway on 19 March. Swiss medtech companies welcomed the move, stressing the need for the defunct mutual recognition agreement to be updated.
A Healthtech Global Software Business With A Silicon Valley Look
Royal Philips’ head of Enterprise Informatics Shez Partovi explains the rationale behind the 2023 decision to set up a vertical business for digital, AI and software applications, to operate alongside imaging, monitoring and interventional therapy.